JNK-IN-8 (GMP)

Cat. No.:	HY-13319G
CAS No.:	1410880-22-6
Molecular Formula:	$C_{29}H_{29}N_7O_2$
Molecular Weight:	507.59
Target:	JNK
Pathway:	MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent JNK inhibitor with IC_{50}s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively[1].
IC_{50} & Target	IC50: 4.7/18.7/1 nM (JNK1/2/3)[1]
In Vitro	JNK-IN-8 (GMP) (10 μM) reduces WNT3A-mediated neuronal differentiation[1]. JNK-IN-8 (GMP) (2 μM, 7 days) enhances the self-renewal of human hematopoietic stem cells (HSCs) through the downregulation of C-JUN phosphorylation[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Nanotechnol. 2021 Jul;16(7):830-839.
- Mil Med Res. 2023 Jun 5;10(1):25.
- Nat Commun. 2020 Jan 3;11(1):71.
- Cell Death Differ. 2020 May;27(5):1569-1587.
- Dev Cell. 2021 Dec 20;56(24):3334-3348.e6.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bengoa-Vergniory N, et al. A switch from canonical to noncanonical Wnt signaling mediates early differentiation of human neural stem cells. Stem Cells. 2014 Dec;32(12):3196-208.

[2]. Xiao X, et al. Targeting JNK pathway promotes human hematopoietic stem cell expansion. Cell Discov. 2019 Jan 8;5:2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA